Lunai Bioworks Launches AI-Powered Alzheimer's Disease Program, Expanding Neurodegenerative Pipeline

Rhea-AI Summary

Lunai Bioworks (Nasdaq:LNAI) launched a preclinical Alzheimer's program using its AI platform Augusta, reporting up to a 35% improvement in diagnostic accuracy by combining MRI, genomics, and metabolomics versus MRI alone. BioSymetrics, a wholly owned subsidiary, signed its first commercial contract last week to identify early Alzheimer's markers. Results were benchmarked on the ADNI dataset and used automated optimization across 22,000 MRI processing runs. The platform supports real-time distributed analysis via cloud architecture and is positioned to extend prior Parkinson's findings into broader neurodegenerative diagnostics.

Positive

• Diagnostic accuracy improvement up to 35% vs MRI alone
• Signed first commercial contract for early Alzheimer's marker identification
• 22,000 MRI processing runs automated for scalable modeling
• Platform validated across multiple neurodegenerative indications

Negative

• Program is currently preclinical with no clinical validation reported
• Results benchmarked on ADNI dataset without disclosed prospective or real-world validation
• No commercial contract value or financial terms disclosed

Insights

Neurodegenerative AI Strategist

Augusta™ shows stronger multimodal AD classification on ADNI; company launches a preclinical program and signed an initial commercial contract.

Lunai Bioworks reports that its Augusta™ platform improved diagnostic accuracy by 35% when combining MRI, genomics, and metabolomics versus MRI alone, benchmarked on the ADNI dataset. The firm is launching a preclinical Alzheimer’s program and a wholly-owned subsidiary, BioSymetrics, signed a first commercial contract to identify early markers of Alzheimer’s disease, according to the October 6, 2025 release.

The immediate business mechanism is clear: integrated, multi-modal machine learning models can yield higher classification performance than single-modality models, and Lunai is packaging that capability into research and commercial offerings. The company also highlights scale features—automated optimization across 22,000 MRI runs and cloud-enabled distributed analysis—which support reproducible, higher-throughput model development.

Caveats and dependencies remain. The reported 35% uplift is measured on ADNI, a specific research cohort; prospective, independent validation is required to establish real-world clinical utility and generalizability. Translation from improved diagnostic classifiers to regulatory acceptance or clinical decision tools requires clinical validation, regulatory engagement, and reproducible performance across diverse populations.

Watch for three concrete items: publication or peer review of the ADNI benchmarking and methods, prospective validation results in independent cohorts, and commercialization milestones tied to the named contract and any regulatory interactions. These will likely play out over the next 12–24 months and determine whether the technical gains become actionable clinical tools.

LOS ANGELES, CALIFORNIA / ACCESS Newswire / October 6, 2025 / Lunai Bioworks (Nasdaq:LNAI) today announced a major advance in Alzheimer's research: its AI platform, Augusta™, achieved up to a 35% improvement in diagnostic accuracy by combining MRI scans with genetic and metabolic data. The company is launching a preclinical Alzheimer's program to bring this technology closer to clinical use, a move that could enable earlier intervention for millions worldwide.

The new program builds on Lunai's recent announcement regarding their findings for Parkinson's Disease, and fulfills their broader vision of applying advanced, multi-modal ML to improve diagnostics in complex disease areas. BioSymetrics, a wholly-owned subsidiary of Lunai and creators of the Augusta platform, is currently engaged in ongoing collaborations with research institutions and pharmaceutical companies to translate these findings into actionable biomarkers and clinical tools, including its first commercial contract to identify early markers of Alzheimer's disease signed last week.

By combining genetic, metabolic, and imaging data using distributed ML pipelines, BioSymetrics has shown that models built on integrated datasets significantly outperform those built on any single modality. This work, benchmarked using the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset, confirms the value of Augusta's proprietary approach to heterogeneous data integration in neurodegenerative disease research.

"I am delighted that we have signed our first commercial deal in our Alzheimer's program. Driving this as our approach reinforces the idea that Alzheimer's Disease is too complex for single-dimensional data," said David Weinstein, CEO of Lunai. "By leveraging AI to integrate and learn from the full biological context, including genetics, MRI imaging, metabolomics, and clinical records, we can generate models that are more predictive, more scalable, and more useful in the search for effective treatments."

Highlights of the work include:

• Platform Expansion: Augusta™ now validated across multiple neurodegenerative indications.

• An up to 35% improvement in diagnostic accuracy when combining MRI, genomics, and metabolomics vs. using MRI data alone.

• Automated parameter optimization across over 22,000 MRI processing runs, enabling scalable precision modeling for diverse patient populations.

• Support for real-time and distributed analysis using cloud architecture.

These results echo previous findings from the literature showing that integrated multi-view models yield the highest performance on AD classification tasks.

About Lunai Bioworks

Lunai Bioworks Inc. is an AI-powered drug discovery and biodefense company pioneering safe and responsible generative biology. With proprietary neurotoxicity datasets, advanced machine learning, and a focus on dual-use risk management, Lunai is redefining how artificial intelligence can accelerate therapeutic innovation while safeguarding society from emerging threats.

Forward-Looking Statements:

This press release contains "forward-looking statements" within the meaning of the Private Litigation Reform Act of 1995 regarding the plans and objectives of management for future operations and market trends and expectations. Forward-looking statements can be identified by the fact that they do not related strictly to historical or current facts. Forward-looking statements are based upon our current assumptions, expectations and beliefs concerning future developments and their potential effect on our business. In some cases, you can identify forward-looking statements by the following words: "may", "could", "would", "should", "expect", "intend", "plan", "anticipate", "believe", "approximately", "estimate", "predict", "project", "potential" or the negative of these terms or other comparable terminology, although the absence of these words does not necessarily mean that a statement is not forward-looking. A forward-looking statement is neither a prediction nor a guarantee of future events or circumstances, and those future events or circumstances may not occur. You should not place undue reliance on forward-looking statements, which speak only as of the date of this Press Release. Forward-looking statements involve known and unknown risks, uncertainties, and other factors, that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The forward-looking statements included herein are based on current expectations and assumptions that involve numerous risks and uncertainties. Our plans and objectives are based, in part, on assumptions involving the continued expansion of our business. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond our control. Lunai Bioworks encourages you to review the risk factors that may affect its future performance in its filings with the Securities and Exchange Commission. We are including this cautionary note to make applicable and take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We expressly disclaim any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Additional information respecting factors that could materially affect the Company and its operations are contained in the Company's filings with the SEC which can be found on the SEC's website at www.sec.gov.

Media Contact:

David Weinstein
Chief Executive Officer
305-918-1980
ir@lunaibioworks.com
http://www.lunaibioworks.com/

SOURCE: Lunai Bioworks Inc.

View the original press release on ACCESS Newswire

FAQ

What improvement did Lunai (LNAI) report for Alzheimer’s diagnostics on October 6, 2025?

Lunai reported up to a 35% improvement in diagnostic accuracy when combining MRI, genomics, and metabolomics versus MRI alone.

Is Lunai’s Alzheimer's program clinically validated or preclinical for LNAI?

The announcement describes a preclinical Alzheimer's program and does not report completed clinical validation.

What commercial progress did Lunai (LNAI) announce on October 6, 2025?

BioSymetrics, a wholly owned subsidiary, signed its first commercial contract last week to identify early Alzheimer's markers; no contract value was disclosed.

Which dataset did Lunai use to benchmark Augusta’s Alzheimer’s results?

The results were benchmarked on the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset.

How has Augusta been scaled for diverse patient populations at Lunai (LNAI)?

Augusta used automated parameter optimization across 22,000 MRI processing runs and supports real-time distributed cloud analysis.

Will the Augusta improvements for LNAI immediately change clinical care for Alzheimer’s?

No; the program is described as preclinical, so clinical impact depends on future validation and regulatory progress.